NEURODEGENERATIVE · SB-C

NEURODEGENERATIVE · SB-C

Remote cognitive assessments for Alzheimer’s clinical trials

Remote cognitive assessments for Alzheimer’s clinical trials

Remote cognitive assessments for Alzheimer’s clinical trials

Validated, automated, speech-based cognitive biomarkers collected via a simple phone call. Delivered at scale in Alzheimer’s Disease (AD) clinical trials to reduce screen failure rates, streamline recruitment, and provide user-friendly, objective measurement. Used today in pre-screening programs and in longitudinal monitoring of cognition.

At a glance

47

Peer-reviewed publications in AD

Peer-reviewed publications in AD

~5

05

Mins per app assessment

Mins per app assessment

~9

09

Mins per call assessment

Mins per call assessment

32

Languages supported

Languages supported

PROBLEM

PROBLEM

PROBLEM

Alzheimer’s
Trial Recruitment

80%

Of AD trials fail to meet enrollment timelines

Of AD trials fail to meet enrollment timelines

30%

Of trial timeline consumed by patient recruitment

Of trial timeline consumed by patient recruitment

$5.9B

Spent annually on trial recruitment globally

Spent annually on trial recruitment globally

<5%

Of eligible candidates are successfully enrolled

Of eligible candidates are successfully enrolled

SOLUTION

SOLUTION

A ~9-minute phone call to streamline participant pipelines

A 9-minute phone call to streamline participant pipelines

A 9-minute phone call to streamline participant pipelines

The Speech Biomarker for Cognition (SB-C) captures highly relevant domains of processing speed, learning & memory, and executive function through a standardized set of spoken tasks. An objective composite score is returned automatically (no clinician, no specialized hardware needed).

The assessment can be used with a voice agent over a standard telephone line, via app, or through a web browser. Participants can complete it from home, in-clinic, or remotely from any global site with high acceptance and usability. Pre-screening using blood-based biomarkers along with the SB-C reduces patient burden, improves screening efficiency, and lowers recruitment costs.

VALIDATION

VALIDATION

Built on a decade of
rigorous clinical validation

DiMe V3 Aligned
DiMe V3 Aligned

SB-C validation follows the Digital Medicine Society’s V3 Framework, covering verification, analytical validation and clinical validation. A full validation package is available for regulatory submissions.

Global dementia cohorts
Global dementia cohorts

Validated using normative data from large scale cohorts and deployed today in worldwide clinical trials and studies. Consistent performance across languages and clinical settings.

Clinical scale and underlying biology anchors
Clinical scale and underlying biology anchors

SB-C results are anchored to established gold-standard clinical measures and fluid biomarkers: ADAS-Cog 13, CDR-SB, MMSE, MoCA, PACC5, Aβ and p-tau181

EVIDENCE

EVIDENCE

Key Publications in Alzheimer’s Disease

Ready to add speech biomarkers to your Alzheimer's trial?

Ready to add speech biomarkers to your Alzheimer's trial?

Ready to add speech biomarkers to your Alzheimer's trial?

Our team works with pharma clinical operations and biomarker strategy teams to model operational efficiencies and support the justification and definition of the endpoint package, for optimized integration of SB-C into your study design.

Our team works with pharma clinical operations and biomarker strategy teams to model operational efficiencies and support the justification and definition of the endpoint package, for optimized integration of SB-C into your study design.

Fastest Path

Fastest Path

Book a 30-minute feasibility call

Discuss your goals, study design, and indications with our team

Book Now

Book Now

Book Now

FREE DOWNLOAD

FREE DOWNLOAD

AD trial pitfalls white paper

Common mistakes in Alzheimer’s clinical trial recruitment and how to avoid them